As a consequence of a reciprocal translocation t(17;22)(q22;q13) and of supernumerary ring chromosomes derived from the t(17;22), a fusion between the platelet-derived growth factor b-chain (PDGF, c-sis proto-oncogene) and the collagen type 1A1 (COL1A1) genes has been recently described in dermato®brosarco-ma protuberans (DP), an in®ltrating skin tumor (Simon et al., 1997) . Although PDGFB has been implicated in transforming processes via autocrine and paracrine pathways, by the activation of the cognate receptor, no direct evidence of its involvement in neoplastic transformation of human tumours has been so far provided. In this report, we have tested the DNA from four DPs in the classical DNA transfection assay onto NIH3T3 ®broblast cell line. All the DNAs induced the formation of transformed foci in the transfected cultures whose derived cell lines were shown to contain a fused sequence comprising the human COL1A1 and PDGF genes. The relative breakpoint regions have been sequenced revealing that this gene fusion deleted exon 1 of PDGF and released the growth factor from its normal regulation. All the biochemical and biological assays were consistent with the model of an autocrine mechanism for NIH3T3 transformation by the human rearranged PDGFB gene involving the activation of the endogeneous PDGF receptor.
Introduction
Deregulation of cell proliferation is an important event underlying the development of human neoplasia and can be determined by changes in factors controlling dierent steps of the cell growth process (Cohen and Ellwein, 1990) . Among those, growth factors acting through autocrine or paracrine mechanisms have been proposed to play a potential important role in cancer development and progression (Weinstein, 1987) .
PDGF is a potent mitogen for cells expressing functional PDGF receptors, typically cells of mesenchymal origin. Several evidences suggest that the PDGFB signalling pathway is implicated in various neoplastic conditions: (1) PDGFB is the cellular homologue of the Simian sarcoma and of the Parodi-Irgens feline sarcoma retroviruses Doolittle et al., 1983; Water®eld et al., 1983) , causing ®brosarcomas and astrocytomas in their host; (2) both v-sis and c-sis are able to transform NIH3T3 cells, when expressed under the control of a viral promoter Clarke et al., 1984; Stevens et al., 1988) ; (3) several tumours of both mesenchymal and epithelial origin, but not their normal counterparts, express PDGFB gene (Peres et al., 1987; Maxwell et al., 1990; Eva et al., 1982) ; (4) dominant-negative mutants of PDGF revert the transformed phenotype of human astrocytoma cells expressing PDGFA, PDGFB and PDGFRb (Shamah et al., 1993) ; (5) structural alterations of the PDGF receptor type b have been reported in chronic myelomonocytic leukaemia and result in a ligand-independent activation of the receptor (Carroll et al., 1996) . Thus, an autocrine system, based on an unscheduled production of PDGFB, has been proposed as the pathogenetic mechanism in a growing list of human tumours; therefore the loss of the PDGFB transcriptional regulation may provide an important contribution to the neoplastic transformation. This hypothesis has been recently supported by a study on human dermato®brosarcoma, a tumour already known to express both PDGFB and PDGFRb (Kikuchi et al., 1993) . In ®ve cases carrying the reciprocal translocation t(17;22) and supernumerary ring chromosomes derived from the translocation, Simon et al. (1997) have reported the presence of a rearrangement involving the collagen 1A and the PDGFB genes. Such rearrangement produced a COL1A1/PDGFB chimeric gene whose product, most likely, is the mature PDGFB.
Despite the tight correlation between the PDGFB expression and cancer, no direct evidences for transforming activity due to a deregulated PDGFB gene have been so far provided. We approached this matter by investigating the transforming activity of the DNA from four dermato®brosarcomas carrying the t(17;22)(q22;q13) translocation (Minoletti et al., 1995) . We found all of them capable to induce foci formation in NIH3T3 cells. Molecular characterization of the transformed cell lines revealed the presence of the COL1A1/PDGFB rearrangement resulting in a chimeric transcript. The transformed cells produce a mitogen factor with autocrine and paracrine eects blocked by inhibitors of the PDGFB activity. Our results suggest that the COL1A1/PDGFB rearrange-ment causes the production of a growth factor whose properties suggest its`PDGFB-like' nature.
Results

Transforming activity of human dermato®brosarcoma DNAs
Transfection of NIH3T3 mouse ®broblasts with high molecular weight genomic DNA from four DPs (one of which was already shown to contain a rearrangement of PDGFB gene intron 1 (Simon et al., 1997) ), yielded a low but reproducible number of transformed foci (range 4 ± 15 foci with 50 mg of DNA, Table 1 ) whereas the control DNA was consistently negative. From primary transfectants of each tumour, DNA was prepared for a second cycle of transfection which resulted in a signi®cant increase of the foci number (range 65 ± 107 foci with 50 mg of DNA, data not shown). Transformed NIH3T3 cell lines from at least three primary foci for each DP were derived and their in vivo tumorigenicity in nude mice was assayed. Although with a dierent growth rate (data not shown), all the cell lines formed tumours in mice injected with 2.5 ± 5610 5 transfectant NIH3T3 cells (Table 1) . Although the obtained tumours were not removed for histological analysis, they macroscopically resembled ®brosarcomas. These tumours were detected 2 weeks after the injection, grew locally, were signi®cantly vascularized and killed the animal without metastasising within 6 weeks after injection.
The DP DNA-induced cell transformation correlates with the presence of a COL1A1/PDGFB rearrangement It has been recently reported that dermatofibrosarcomas carry a rearrangement linking the COL1A1 gene to PDGFB and, most likely, resulting in the deregulation of the growth factor (Simon et al., 1997) . To assess whether the transforming activity of the DP analysed was related to the COL1A1/PDGFB rearrangement, we performed PCR analysis on primary NIH3T3 transformants DNA. In Figure 1 a PCR analysis showing the detection of human COL1A1 exon 1 sequences in the transfectants of all DPs is reported. Similarly, Figure 1b shows, in the same cell lines, the presence of the human PDGFB exon 4. The PCR conditions in both cases allowed us to detect the human sequences, as demonstrated with HeLa and NIH3T3 DNAs as positive and negative controls, respectively. In addition, Southern blot analysis with the v-sis probe demonstrated the presence of the PDGFB gene in the DNA of the primary transformants (data not shown). These data show that human COL1A1 and PDGFB sequences co-segregated with the transformed phenotype and suggest that, as previously reported (Simon et al., 1997) , COL1A1 and PDGFB can be fused to form a chimeric transforming sequence which results in a constitutive Figure 1 Detection of PDGFB and COL1A1 human sequences in NIH3T3 DP-transformants by PCR ampli®cation. High molecular weight DNA (1 mg) was subjected to PCR ampli®cation with oligonucleotides AGexpdgf3 and AGexpdgf4 (top), AGintcol1a and Agintcol1b (bottom) as described in Materials and methods. At least three independent foci derived from each DP were analysed. NIH3T3 and HeLa DNA were used as negative and positive control, respectively. In the transformant cell lines denomination, the number refers to the case number from whose DNA transfection they were originated expression of human PDGFB. We have therefore analysed by RT ± PCR the NIH3T3 transformants for the presence of human PDGFB-related transcripts. Figure 2a shows that in all the transfectants the 174 bp band representing exon 4 of the gene was present, whereas no such band was ampli®ed in the control. Northern blot analysis of total RNA with the PDGFB cDNA as probe showed very faint, barely visible signals (data not shown), thus accounting for a low expression of the PDGFB-related mRNAs.
Subsequently, we demonstrated the presence of COL1A1 and PDGFB chimeric transcripts in the transformed cells derived from all tumours analysed. By multiplex PCR (see Materials and methods) we have identi®ed and sequenced bands of 290 bp (case 4), 540 bp (cases 5 and 7) and 167 bp (case 6) ( Figure  2b ). All the ampli®ed fragments contain PDGFB exon 2 preceded by COL1A1 sequences belonging to exon 24 (case 6), exon 29 (case 4) and exon 32 (cases 5 and 7) (Figure 2b) . In all the cases the translation of COL1A1 is in frame with that of PDGFB. These ®ndings predict the intron involved in the dierent rearrangements (intron 24, 29 and 32, respectively). Figure 2c shows the localization of the breakpoints in all the analysed cases, including those reported in a previous study (Simon et al., 1997) . Whereas the breakpoints in PDGFB gene all occur within intron 1, in COL1A1 gene they are scattered within a broad region containing introns 9 ± 43. Six dierent COL1A1 introns (8, 11, 24, 29 32 and 43) may be involved in rearrangements with PDGFB; introns 29 and 32 are involved in two and three dierent rearrangements, respectively (Figure 2c ).
DP-induced NIH3T3 foci produce a`PDGFB-like' mitogenic factor
To investigate whether the phenotype of the NIH3T3 cells transformed by the DP DNAs and therefore most likely also the development of DPs, are due to an autocrine stimulation involving PDGFB and its receptor, we performed several biological and biochemical studies. The NIH3T3 DP-transformed cell lines were able to undergo DNA synthesis in serum-free medium, as demonstrated by the incorporation of [ Figure 3 , we detected stimulation of DNA synthesis, indicating that the transformed cells produce a secreted mitogenic factor. The addition of suramin (an agent inhibiting the ligand/receptor interaction at the cell surface, known to inhibit also the PDGF mitogenic activity and to revert the v-sis transformed phenotype (Betsholtz et al., 1986) ), caused a reversion of the transformed phenotype of the NIH3T3 transformants ( Figure 5 ) and inhibited the DNA synthesis of the same cells in serum-free medium and of NIH3T3 control cells exposed to conditioned medium ( Figure  4) , indicating that the interaction of the factor and its receptor occurs at the cell surface. Moreover, very recently it has been shown that K252a, a microbial alkaloid known to inhibit TRK tyrosine kinase activity (Tapley et al., 1992) , speci®cally blocks the PDGFB signalling in a glioma cell line (Chin et al., 1997) . We treated the DP DNA-transformed NIH3T3 cells with K252a and observed a transient reversion of the transformed phenotype ( Figure 5 ) and the inhibition of the DNA synthesis in serum-free medium (Figure 3 ). These ®ndings support the notion that the autonomous growth of the NIH3T3 transformants was supported by the activation of a TK receptor by an endogeneously produced ligand. We did not succeed in demonstrating the presence of the PDGFB protein in these DP-transformed NIH3T3 cell lines and in their conditioned medium by Western blot analysis, most likely because the amount of the factor is below the detection level, as determined in control experiments with puri®ed PDGFB (data not shown). However, all the evidences above reported, together with the demonstration of the presence, in the transfected cell lines, of a human COL1A1/PDGFB chimeric transcripts, suggest that the COL1A1/PDGFB rearrangement causes the unscheduled production of PDGFB which, in turn, triggers a signal transduction pathway leading to cellular transformation by activating its cognate receptor. 
Discussion
The ®rst indication of PDGF involvement in cancer was provided by its homology with v-sis, the oncogenic retrovirus isolated from a simian sarcoma Doolittle et al., 1983; Water®eld et al., 1983) . In human cancer no direct proof of malignant transformation, due to PDGFB alterations and/or deregulation, has been so far provided. However, there is a large body of evidence for a potential role of PDGFB in tumour growth (Westermark and Sorg, 1993) . A PDGFB autocrine system, based on the production of the factor, has been proposed as the pathogenetic mechanism in a growing list of human tumours, including prostate carcinoma (Camby et al., 1994) , soft tissue tumours (Weiner et al., 1994; Wang et al., 1994) , leukaemia (Tsai et al., 1994; Golub et al., 1994) and glioma (Hermanson et al., 1992; Westermark et al., 1995) . In addition, alterations of the PDGFB receptor, resulting in a constitutive activation, have been reported in chronic myelomonocytic leukaemia (Carroll et al., 1996) . All these ®ndings suggest that deregulation of the PDGFB signalling may play a role in transformation.
Dermato®brosarcomas is an in®ltrating tumour of the skin characterized by speci®c cytogenetic features: a translocation t(17;22)(q22;q13) and supernumerary ring chromosomes derived from the t(17;22) (Pedeutour et al., 1993 (Pedeutour et al., , 1996 . In addition, DP cells express PDGFRb in vivo and in vitro and produce a protein reacting with PDGFB antibodies (Kikuchi et al., 1993) . Recently, Simon et al. (1997) have reported that the DP-speci®c t(17;22) translocation creates a molecular aberration by juxtaposing dierent portions of the COL1A1 gene to the second exon of PDGFB gene. The resulting chimeric gene encodes a COL1A1/ PDGFB transcript whose product contains the entire sequences for the processing of PDGFB; the ®nal product is, most likely, the mature PDGFB. The authors propose that such rearrangements release the PDGFB from its physiological control and the unscheduled production of PDGFB creates an autocrine mechanism responsible for the development of DP.
To provide a formal proof that the COL1A1/ PDGFB rearrangement is sucient for transformation of the aected cells, we transfected four DP DNAs into NIH3T3 cells. The latter express PDGF receptors and are therefore adequate recipient cells to detect an autocrine mechanism leading to transformation. The DNA of all the DP analysed, previously shown to contain the t(17;22) translocation (Minoletti et al., 1995) , was able to induce NIH3T3 transformation. The molecular analysis of the derived transformed cell lines revealed the presence of a COL1A1/PDGFB rearrangement. Chimeric transcripts were detected in all the cases; they resulted from the fusion of PDGFB exons 2 ± 7 preceded by dierent portions of the COL1A1 gene. Our results, together with the previously reported COL1A1/PDGFB rearrangements, indicate that the oncogenic rearrangements involve dierent exons of COL1A1 gene, and, constantly, only the ®rst intron of PDGFB gene. These features are consistent with a normal processing of PDGFB protein whose mature form is produced by a proteolitic cleavage of a precursor with the peptidase-recognition sites encoded by exons 3 and 6 of PDGFB gene (Simon et al., 1997) .
To assess whether the transforming activity of the COL1A1/PDGFB rearrangement was due to an unscheduled production of PDGFB we performed several biological and biochemical studies. The ability of the transformed foci to grow in serum-free medium, the mitogenic eect of the conditioned media and the sensitivity of the transformed phenotype as well as of the mitogenic activity to suramin treatment, all suggest that a mitogenic factor, with autocrine and paracrine properties, is secreted by the DP-transformed cell lines and interacts with its receptor at the cell surface. The eect of K252a on the transformed phenotype and the phosphorylation of the PDGFRb in serum-free medium suggest that such factor is PDGFB. This could indicate, as already suggested by Simon et al. (1997) , that the processing and maturation of the COL1A1/PDGFB chimeric protein may be the same of the normal PDGFB. The low level of PDGFB produced in NIH3T3 transformants has however prevented the detection, by Western blot, of any product reacting with the anti PDGFB antibody; therefore, the biochemical study of the COL1A1/PDGFB processing remains to be determined.
We have demonstrated, in conclusion, that dermato®brosarcomas carrying the t(17;22) translocation express a COL1A1/PDGFB chimeric transforming sequence encoding a protein with eects similar to those of normal PDGFB. To our knowledge this provides the ®rst direct evidence for the transforming activity of PDGFB from human tumours. It is worth emphasizing how studies on dermato®brosarcoma, from the initial observations of speci®c cytogenetic abnormalities, have lead to the identi®cation of a gene rearrangement as genetic marker and have also unveiled the alteration of a physiological mechanism as responsible for the transformation process. These ®ndings allow us to establish animal models carrying tumours induced by the genetic alterations detected in DP. Given that the PDGFB pathway is well known and several chemical compounds blocking the PDGFB signalling are available, it is therefore reasonable to expect that, in the next future, following the ®ndings reported in this paper, therapies speci®c for DP could be designed.
Materials and methods
Cell culture and transfection
Mouse NIH3T3 ®broblasts and transformed cell lines were maintained in Dulbecco's modi®ed Eagle medium supplemented with 10 and 5% calf serum, respectively. NIH3T3 cells (2.5610 5 /10-cm plate) were transfected with 50 mg of tumour DNA by the CaPO 4 method, as previously described (Bongarzone et al., 1989) . Foci were ®xed or isolated for further analysis 3 weeks later. Suramin (Calbiochem) was dissolved in water and stored at room temperature. K252a (Calbiochem) was prepared as previously reported (Greco et al., 1993) . Conditioned medium was prepared by incubating subcon¯uent cultures of transformed foci in 0.1% serum medium for 2 days. The medium was used immediately or stored at 7808C. 3 H]thymidine (Dupont) at 10 mCi/ml was added, in combination or not with suramin (100 mM) or K252a (500 mM). The cultures were incubated for 24 ± 30 h and then harvested for liquid scintillation counting.
Tumorogenicity assay
NIH3T3 foci were harvested and resuspended in DMEM. Aliquots containing 2.5610 5 and 5610 5 cells were injected subcutaneously into 5 ± 7 weeks-old athymic nude mice (CDI nu/nu; Charles River). Mice were inspected for 6 weeks; tumour growth was evaluated at days 14 and 24 after injection.
Nucleic acid extraction
High molecular weight DNA was extracted following standard procedures (Sambrook et al., 1989) . Total RNA was prepared by the RNAzol tm method (Biotecx Laboratories, Inc.).
PCR and RT ± PCR analysis of NIH3T3 foci
To amplify COL1A1 and PDGFB human sequences, the following sets of primers were used: AGintcol1a (5'-TTCCTCCCTGCTCTCCATCA-3') and AGintcol1b (5'-CACTCCCAAAAGTTTGGGACT-3'); AGexpdgf3 (5'-TTCCCTGACCATTGCTGA-3') and AGexpdgf4 (5'-ACTGCACGTTGCGGTTGTTT-3').
High molecular weight DNA (1 mg) was used as template. For RT ± PCR analysis RNA (2 mg) was reverse transcribed by using the cDNA Synthesis System kit (GIBCO ± BRL). To detect the expression of PDGFB gene, 2 ml of ®rst-strand cDNA were ampli®ed with primers AGexpdgf3 and AGexpdgf4. To detect the presence of COL1A1/PDGFB chimeric transcripts, multiplex PCR reaction was performed. Two microliters of ®rst strand cDNA were ampli®ed using the primer pdgfext (5'-GCGCTGCACCTCCACACAG-3') together with four external COL1A1 primers: colext1 (5'-GCCAAGACGAAGACATCCC-3'), colextag1 (5'-CTG-CTGGTGCTCGTGGAAAT-3'), colext2 (5'-CCCCTGGC-GAGCGTGGTGG-3'), colextag3 (5'-CCATTGGTAA-TGTTGGTGCT-3'). A 5 ml aliquot of the ®rst PCR was used as template in four separate nested PCR reactions using the primer pdg®nt (5'-TCAAAGGAGCGGATC-GAGT-3') in combination with four dierent internal COL1A1 primers: colintag2 (5'-TGCTAAGGGT-GAAGCTGGTC-3'), colint2 (5'-AAGGTGCTGCTGGA-GAGCC-3'), colintag4 (5'-TCTGGAAATGCTGGACCC-3') and colint5 (5'-CCCGACGGCTCAGAGTCA-3'). The template was mixed with 16PCR buer (Perkin Elmer), 450 pM each primer, 150 mM each deoxynucleotide triphosphate (dNTPs), 1.6 mM MgCl 2 1.5 units of Taq polymerase (Perkin Elmer) in a ®nal volume of 50 ml. After an initial denaturation (958C for 3 min), 35 cycles of PCR were carried out (958C for 1 min, 558C for 50 s, 728C for 90 s), followed by a ®nal extension of 5 min at 728C. Twenty-®ve microliters of the PCR product were electrophoresed on 4% agarose gel.
DNA sequencing
The PCR product (25 ml of standard reaction) were sequenced on the ABI 377 sequencer using ABI PRISM TM dye terminator (Perkin Elmer).
Western blot analysis
Cell lysates were prepared as described elsewhere (Borrello et al., 1994) . After immunoprecipitation with the anti PDGFBRb antibody (UBI), the protein samples were electrophoresed on a sodium dodecyl sulphate (SDS)-polyacrylamide gel (6.5%), transferred to nitrocellulose ®lters and immunoblotted with the anti PDGFRb (UBI) or the antiphosphotyrosine (UBI) antiserum. Immunoreactive bands were visualized by using horseradish peroxidaseconjugated secondary antiserum and enhanced chemiluminescence (Amersham).
